Company profile for Tegmine Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Tegmine targets glycoproteins, a hallmark of aggressive solid cancers, to create next-generation antibody-based therapies that enhance efficacy and reduce toxic side effects. Using its proprietary TegMiner™ platform, the company discovers unique cancer epitopes and develops life-changing antibodies to address critical unmet patient needs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
4104 24th St., Suite PMB 405 San Francisco, CA 94114
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Natural Product Expo West

Natural Product Expo West

Not Confirmed

envelop Contact Supplier

Natural Product Expo West

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/06/06/3094901/0/en/OBI-Pharma-Enters-ADC-Collaboration-with-TegMine-Therapeutics-utilizing-GlycOBI-and-TegMiner-Enabling-Technologies.html

GLOBENEWSWIRE
06 Jun 2025

https://www.businesswire.com/news/home/20220406005182/en

BUSINESSWIRE
06 Apr 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty